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The spatial control of optical absorption provided by two-
photon excitation (TPE) has led to tremendous advances in 
microscopy
1 
and microfabrication
2
. Medical applications of 
TPE in photodynamic therapy (PDT)
3,4
 have often been 
suggested
5-18
, but have been made impractical by the low two-
photon cross-sections of photosensitiser drugs (i.e. compounds 
taken up by living tissues that become toxic on absorption of 
light). The invention of efficient two-photon activated drugs will 
allow precise manipulation of treatment volumes in three 
dimensions, to a level unattainable with current techniques. 
Here we present a new family of PDT drugs designed for 
efficient TPE, and use one of them to demonstrate selective 
closure of blood vessels via TPE-PDT in vivo. These conjugated 
porphyrin dimers have two-photon cross-sections that are more 
than two orders of magnitude greater than those of clinical 
photosensitisers
17
. This is the first demonstration of in vivo PDT 
using a photosensitiser engineered for efficient two-photon 
excitation. 
Photodynamic therapy is used to treat diseases characterised by 
neoplastic growth including various cancers, age-related macular 
degeneration (AMD) and actinic keratosis
3,4
. Cell death is induced 
by photoexcitation of a sensitiser, generally via production of 
singlet oxygen. In the absence of light the photosensitiser is benign, 
so systemic toxicity is rare and treatment may be repeated without 
acquired resistance. Two-photon excitation of the photosensitiser 
should allow greater precision than is attainable by conventional 
one-photon excitation, as a consequence of the quadratic 
dependence of TPE on the local light intensity — the amount of 
TPE is inversely proportional to the fourth power of the distance 
from the focus. In addition, the longer wavelengths associated with 
TPE allow treatment deeper into tissue, by minimising absorption 
from endogenous chromophores.  
High instantaneous photon densities are essential for two-photon 
excitation. Early TPE-PDT studies used nanosecond lasers, but the 
dominant effect was photothermal damage
5-7
. The advent of 
commercial femtosecond tuneable Ti:sapphire lasers has greatly 
facilitated the investigation of TPE-PDT, and the limiting factor has 
become the availability of suitable photosensitisers. The majority of 
chromophores possess low two-photon cross-sections, of the order 
of 1–100 Goeppert-Mayer units (1 GM = 10
–50 
cm
4
 s photon
–1
). For 
example, the two FDA-approved PDT photosensitisers, verteporfin 
and Photofrin (cross sections 50 GM and 10 GM respectively)
17
, are 
unlikely to be suitable for TPE-PDT, as the high light intensities 
needed to achieve a therapeutic effect are close to the thresholds for 
photothermal or photomechanical damage
18
. 
Several design strategies for TPE-PDT photosensitisers have 
been reported recently
11-16
, but few of these compounds have yet 
been studied in vitro
15
, and, to date, none have progressed to in vivo 
testing. Porphyrin derivatives are often effective PDT agents, as 
exemplified by verteporfin and Photofrin
4
. Recently it has been 
found that the two-photon cross-section of a porphyrin can be 
increased 500-fold by forming a conjugated porphyrin dimer
19-21
, 
and that these dimers have high singlet oxygen yields
20,22
. Here we 
show that porphyrin dimers can be functionalised with polar 
substituents to give effective TPE-PDT drugs. 
We have tested a family of related anionic and cationic 
conjugated porphyrin dimers 1–5. The structures of these 
compounds are shown in Fig. 1, together with their one-photon and 
two-photon absorption spectra. Polar terminal substituents were 
added to facilitate delivery to cells. In the case of 1 and 4, the 
conjugated electron-accepting aromatic terminals also shift the one-
photon and two-photon absorption to longer wavelengths and 
intensify the two-photon absorption (!max 17,000 GM at 916 nm for 
1). The singlet oxygen quantum yields, in methanol, are: 0.60, 0.54, 
0.70, 0.16 and 0.69 for 1–5 respectively, showing that they all have 
potential as PDT agents. All five compounds are readily internalised 
by human ovarian adenocarcinoma cells (SK-OV-3), and exhibit 
punctate fluorescence in the cytoplasm (supplementary information 
Fig. S2). One-photon PDT experiments (Fig. 2a) show that while 
the anionic dyes 4 and 5, have limited PDT activity, the cationic 
compounds 1–3 are comparable to verteporfin 6. The photodynamic 
efficiencies of compounds 1–3 were investigated in detail, including 
the effect of incubation time, concentration and light dose 
(supplementary information Fig. S3). Compound 1 was selected as 
the most promising candidate because of its high PDT potency, 
rapid up-take by cells and high two-photon cross-section.  
TPE-PDT experiments with dimer 1 were carried out on SK-OV-
3 cells, using a Ti:sapphire laser (920 nm, 300 fs, 90 MHz). A 
confocal microscope was used to irradiate a monolayer of cells and 
to determine survival by fluorescent staining
17
. The quadratic 
dependence of the therapeutic effect on the laser intensity (Fig. 2b) 
confirms that, PDT is achieved via TPE. Under two-photon 
excitation, porphyrin dimer 1 is substantially more phototoxic than 
verteporfin and requires only 260 scans to kill 50% of the cells, 
 
Figure 1 ! Structures and absorption spectra of conjugated 
porphyrin dimers 1–5, and the clinical photosensitiser verteporfin, 6; (a): 
one-photon absorption spectra of 1, 2, 4 and 6, and (b) two-photon 
absorption spectra of 1–4. The spectra of 3 and 5 are almost identical to 
those of 2. All spectra were recorded in dimethylformamide (DMF) with 
1 % pyridine.  
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whereas 430 scans are required with verteporfin (4.2 mW laser 
power, supplementary information Fig. S5).  
TPE-PDT holds particular promise for the targeted closure of 
blood vessels associated with neoplastic diseases, especially for the 
treatment of complex organs such as the eye or brain, where high 
spatial selectivity is crucial
10,18
. We sought to test the selective 
closure of blood vessels in vivo with photosensitiser 1, using the 
dorsal skinfold window chamber model for non-invasive 
visualisation of blood vessels
24
. The inner skin layer of a male 
athymic nude mouse (NCRNU-M, Taconic) was removed from a 10 
mm diameter region and a titanium saddle was sutured in place to 
hold the skin flap vertically away from the body. The exposed facial 
plane and associated vasculature were protected with a glass 
coverslip (145 ± 15 µm thick). Surgery and treatment were carried 
out under continuous ketamine-xylazene aesthesia. Porphyrin dimer 
1 was administered via the tail vein in 5 % dextrose solution and its 
fluorescence was imaged through the window (Fig. 3a). The 
 
 
Figure 2 ! In vitro photodynamic therapy. (a) One-photon  
photodynamic efficiencies of porphyrin dimers 1–5, compared to 
verteporfin, 6. Human ovarian adenocarcinoma cells (SK-OV-3) were 
incubated with 10 µM of each photosensitiser for 6 h and irradiated with 657 
nm light, 3.2 mW, 20 min. Cell viability was determined using a MTT 
assay23. Neither light nor drugs were individually toxic to the cells at these 
doses; average cell viability 97% ± 12 and 101% ± 12 respectively (error 
bars: 1 s.d.). (b) Two-photon photodynamic efficiency of 1 as a function of 
laser power, determined as in Khurana et al.17 (error bars: 1 s.e.). The 
SK-OV-3 cells were incubated for 18 h, with 10 µM of 1 and irradiated with 
920 nm, 300 fs, 90 MHz light. The light dose (number of scans) required to 
kill 50% of the cells (LD50), was determined using 3.6, 4.2, 4.9, 5.8 and 6.8 
mW powers (supplementary information Fig. S4), and log[LD50] is plotted 
against log[laser power–1]. The gradient of the linear fit to these points is 2.0 
± 0.2, confirming two-photon activation. 
 
 
Figure 3 !  Fluorescence from photosensitiser 1 in vivo. (a) Wide-
field in vivo fluorescence image ("ex 445–490 nm, "em 690–940 nm in 10 nm 
bands, Maestro, CRi) of 1 through the window chamber, 1 h post tail vein 
injection, 10 mg kg–1 (scale bar: 1 mm). Photosensitiser 1 was prepared from 
a 10 mM stock in DMSO diluted with 5 % dextrose (Baxter). 
Autofluorescence was subtracted from the images by deconvolution. (b) The 
resulting emission spectrum of 1 in the blood (—), and the corresponding 
emission spectrum in DMF with 1% pyridine (- - -).  
 
Figure 4 ! In vivo two-photon blood vessel closure with photosensitiser 1. Mice bearing dorsal window chambers were administered 10 mg kg-1 of 
1 diluted from a 10 mM stock in DMSO. A selected artery was targeted with 920 nm light (< 3 mW) guided by the striations caused by blood flow visible in the 
transmission image (supplementary information Fig. S7). An 83 " 83 " 40 µm volume was irradiated 4 times (39 mW) as a stack of 5 planes, 10 µm apart; each 
plane consists of 512 " 512 pixels; dwell time: 0.8 !s per pixel. a, Pre-treatment confocal (5", 0.25 numerical aperture) transmission (left, "ex 543 nm), TRITC-
dextran fluorescence (middle, "ex 543 nm, "em 565–615 nm) and superimposed (right) images (scale bar 200 µm). b, Images immediately after TPE-PDT with 1 
(scale bar 200 µm) and c, expanded image of irradiated area (scale bar 100 µm). d, Pre-treatment stereomicroscope image of the entire dorsal window chamber 
(scale bar 1 mm) and e, post-treatment image (scale bar 200 µm). 3D-rendered images of blood flow produced by Doppler OCT imaging f, pre- and g, post-
treatment (scale bar 400 µm), overlaid on pre-treatment stereomicroscope image. The blood flow in the targeted artery is from left to right. The white boxes 
indicate the irradiated region. 
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emission spectrum of 1 in the blood stream matches that recorded in 
DMF (Fig. 3b), although the in vivo spectrum is slightly broader.  
To demonstrate closure of blood vessels using two-photon PDT, 
we selected arteries with a diameter of 40 ± 5 µm. Laser light (920 
nm, 300 fs, 90 MHz, 39 mW) was focussed by a 5", 0.25 numerical 
aperture air lens. With this objective, the 1/e radius of the two-
photon excitation volume was calculated to be 0.83 µm laterally and 
11 µm axially
1
. A section of the artery was irradiated as a series of 
five 83 " 83 µm images, each 10 µm apart through the depth of the 
vessel. As is used clinically with verteporfin-PDT treatment of 
AMD, the light dose was applied a short time (15 min) after 
injection of the photosensitiser
25
. An additional fluorescent marker, 
tetramethylrhodamine (TRITC) labelled dextran, was also used to 
facilitate confocal imaging of blood vessels. Mice treated with 10 
mg kg
–1
 of photosensitiser 1 and 15 mg kg
–1
 of TRITC-dextran 
showed vessel thinning during irradiation and the blood flow ceased 
after 7–12 min continuous raster-scanning; the entire light dose was 
delivered over 15 min. Immediately after irradiation the artery 
appeared thinner, and a segment of the vessel approximately 100 
µm either side of the centre of the irradiated region was no longer 
visible in the transmission image (probably due to the exclusion of 
haemoglobin), Fig. 4a–c. Although the occluded length of the artery 
is longer than the irradiated region, surrounding blood vessels 
appear unaffected. Loss of blood vessel function was confirmed by 
injection of 5 mg kg
–1
 fluorescein labelled dextran after treatment. 
Fluorescence from this second blood tracer was seen in the 
surrounding vessels and in the unexposed length of the artery, 
though the irradiated section remained dark (supplementary 
information Fig. S8).  
Blood vessel closure by injection of 10 mg kg
–1
 of 1 and 
irradiation with light for 15 min was reproducible, with all 3 
animals in the treatment group exhibiting the same outcome 
(supplementary information Fig. S9). Two additional control groups 
of three similar sized arteries were exposed to the same light dose. 
The first group of animals were administered only the TRITC-
dextran blood contrast agent (15 mg kg
–1
). Transmission and 
fluorescence microscopy confirmed that there were no visible 
effects to the vessels, proving that the artery closure observed with 
1 is not thermal in origin. The remaining group of three animals 
were injected with the same amount of active photosensitiser (3.25 
mg kg
–1
 verteporfin 6, formulated as 180 mg kg
–1
 of Visudyne®). 
Significantly, vessel closure could not be induced using prolonged 
exposure to 920 nm light and verteporfin (supplementary 
information Fig. S10).  
For one animal in each treatment group (10 mg kg
–1
 of 1, 3.25 
mg kg
–1
 verteporfin, control) the blood flow pre- and post-
irradiation was monitored by optical coherence tomography (OCT, 
Fig. 4f–g)
26
. A swept laser source scanning 1260–1360 nm was 
used to map the tissue structure at near histological resolution (~10 
µm) by spectral reflectometry. In addition the Doppler frequency 
shift
27,28
 induced by moving red blood cells was used to measure the 
flow velocity as low as 100 µm s
–1
. For animals administered 
TRITC-dextran with or without verteporfin the blood flow remained 
unaltered by the light dose (supplementary information Figs. 10, 11). 
In contrast, the flow reduced from 7000 µm s
–1
 to <100 µm s
–1
 in 
the treated region of the animal administered 1 (supplementary 
information Table S1). Three-dimensional images showing the 
surfaces of the blood vessels were constructed for each animal from 
1000 transverse scans. The occlusion of the blood vessel by two-
photon PDT is clearly evident in the rendered image, Fig. 4f–g.    
In summary, we have synthesised a new family of PDT 
sensitisers derived from porphyrin-based molecular wires with high 
two-photon cross-sections. The in vitro two-photon efficacy of 
compound 1 offers a significant improvement over the commercial 
photosensitiser verteporfin 6. This is the first time a photosensitiser 
designed specifically to have a high two-photon cross-section has 
been shown to be effective in vivo, and the first demonstration of 
TPE-PDT in a living mammal. Although the energy density 
required for two-photon vessel-closure with near-IR light is higher 
than would be required for one-photon closure with visible light, 
there is no detectable photothermal damage because the tissue is 
essentially transparent at the illumination wavelength (920 nm). 
This study highlights the feasibility of two-photon photodynamic 
therapy as a new strategy for targeted occlusion of blood vessels.   
METHODS 
Two-photon absorption spectra were measured by means of 
fluorescence intensity (justified by Vavilov–Kasha’s rule). For two-photon 
excitation, we used linearly polarized light from a tuneable femtosecond 
optical parametric amplifier (TOPAS, Quantronix) and recorded the 
fluorescence emission of freshly prepared samples (ca. 1 !M solution in a 1 
cm cuvette) in 90° geometry as a function of excitation wavelength with an 
imaging spectrometer (Triax 550, Jobin-Ivon). Spectra were corrected for 
the wavelength dependence of photon flux, pulse duration, and beam spatial 
profile. These spectra were scaled to the cross-section (!), measured at a 
selected wavelength. For ! measurement, we compared the intensities of 
one- and two-photon excited fluorescence under the same conditions of 
registration and similar excitation geometry.29 
Singlet oxygen quantum yields were determined with reference to 
chlorophyll a in methanol (0.77)30 by excitation with 450 nm, 9 ns, 10 Hz, 
0.05–3 mW light from a pulsed dye laser (Lambda Physik with coumarin 
120 in methanol) pumped by a frequency doubled Nd:YAG laser 
(Continuum Surelite I-10). The singlet oxygen luminescence at 1270 nm 
was detected perpendicular to the excitation beam using a cooled photodiode 
(E0817-P North Coast) and the signal was averaged and recorded using a 
digital oscilloscope (Tektronics TDS 3012). 
Confocal microscopy. A laser scanning microscope (LSM 510 Meta 
NLO, Zeiss) equipped with argon ion (488 nm), He-Ne (543 nm) and 
Ti:sapphire lasers (Chameleon, Coherent, tuneable from 730 nm to 960 nm, 
300 fs, 90 MHz) was used for confocal imaging and two-photon irradiation. 
In vitro studies used a 40", (NA 1.2, water immersion) objective and the 
cells were maintained at 37 °C. A 5" (NA 0.25) was used for in vivo work, 
and the mice were maintained normothermic at 30 °C. 
In vitro imaging. SK-OV-3 cells (ECACC) were grown in phenol red free 
DMEM (Gibco) supplemented with 2 mM L-glutamine, 100 U mL–1 
penicillin (Sigma), 100 µg mL–1 streptomycin (Sigma) and 10 % fetal bovine 
serum (Sigma). The cells were maintained at 37 °C in a humidified 5 % CO2 
atmosphere. The cells were detached from the flasks with a solution of 
0.05 % w/v trypsin (Gibco) and seeded, 2.4 " 105 cells in 400 µL of medium, 
in untreated 8-well coverglass chambers (Lab-TekTM chambered coverglass, 
Nunc) and allowed to grow to confluence over 3 days. The localisation of 1 
was determined after 4 h incubation with 10 µM diluted in culture medium 
from a 1 mM stock in DMSO ("ex 458 nm, "em 650–710 nm).  
In vitro phototoxicity. SK-OV-3 cells were seeded in flat 96-well plates 
(Nunc), 1250 cells per well in 100 µL of media and irradiated 26 h later. At 
the required time before the light dose, the media on the cells was replaced 
with the photosensitiser solution. The plates were shielded from light during 
and after incubation. The wells requiring light exposure were irradiated with 
657 nm LEDs (3.2 mW, Dotlight GbR, Germany), then washed (3 " 100 µL 
media) and incubated in 100 µL of media for 42 h. After this time the cell 
viability was determined using a proliferation assay (CellTiter 96# Aqueous, 
Promega). An average background absorbance reading of the media was 
recorded and subtracted from the average absorbance of each replicate group. 
Each experiment consisted of at least 5 replicates, and every experiment was 
repeated at least three times.  
Mice. All in vivo work was performed with ca. 20 g nude male NCRNU-M 
(Taconic) mice, anesthetised with 80 mg kg–1 ketamine and 13 mg kg–1 
xylazine i.p., kept anesthetised with 30 min injections of quarter this dose, in 
accordance with approved protocol 1311.4 of the University Health Network, 
Toronto. Dorsal window chambers were installed as described previously24. 
Stereomicroscopy. Pre- and post-irradiation the vasculature of the 
window chamber was imaged using a stereomicroscope (MZ FLIII, Leica). 
1" magnification, white light mode 
Optical coherence tomography was performed using a 24 kHz swept 
source OCT system (OCM1300SS, Thorlabs) with an isotropic spatial 
resolution of 10 µm. 3D image stacks were acquired before and after two-
photon light exposure in a 1 mm3 cubic volume of interest. The irradiated 
regions were selected using the real-time colour Doppler mode to identify 
blood vessels. Both structural and Doppler images were collected and 
processed for peak blood flow velocity estimation and 3D rendering. 
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Doppler background noise was first minimized using a histogram rejection 
algorithm after which the peak blood flow velocity estimates were made28. 
For 3D visualizations a consecutive series of segmented blood vessels 
images was used to reconstruct the vessel surfaces, which were subsequently 
rendered using image processing software (Amira 4.1.1, Mercury Computer 
Systems). 
Two-photon irradiation of arteries: Before irradiation mice bearing 
window chambers were injected with 15 mg kg–1 of 2,000,000 MW dextran 
labelled with tetramethyl rhodamine (Molecular Probes) and a maximum of 
two arteries with a diameter of 40 ± 5 µm were selected by confocal 
fluorescence microscopy ("ex 543 nm, "em 565–615 nm). For the treatment 
groups mice were administered by tail vein injection either 10 mg kg–1 of 1 
diluted from a 10 mM stock in DMSO or 3.25 mg kg–1 of verteporfin with 
TRITC-dextran. The verteporfin was administered as the clinical 
formulation Visudyne® (QLT Inc.): 180 mg kg–1 of Visudyne® was used as it 
contains 3.25 mg kg–1 of verteporfin, an equivalent photosensitiser dose as 
used with 1, scaled to account for their differing molecular weights. The 
artery was focused using 920 nm light (< 3 mW) and an 83 " 83 µm region 
was irradiated (39 mW) as a vertical stack of 5 images, each 10 µm apart. A 
minimum of 1 h post irradiation 5 mg kg–1 of 464,000 MW dextran labelled 
with fluorescein (Sigma) was injected in 100 µL of 5 % dextrose and imaged 
15 min later ("ex 488 nm, "em long pass 505 nm). 
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